BetterLife Pharma Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Our common stock is quoted on the Canadian Securities Exchange, listed for quotation on December 19, 2017, under the Symbol “PVOT”. Our common stock is also quoted on the OTCQB, listed for quotation on April 13, 2010, under the Symbol “PVOTF”. The following table reflects the high and low bid information for our common stock obtained from Stockwatch and reflects inter-dealer prices, without retail mark-up, markdown or commission, and may not necessarily represent actual transactions. The high and low bid prices of our common stock for the periods indicated below are as follows: OTC Bulletin Board (1) Quarter Ended High (US$) Low (US$) January 31, 2019 $ 0.363 $ 0.080 October 31, 2018 $ 0.500 $ 0.091 July 31, 2018 $ 0.640 $ 0.209 April 30, 2018 $ 2.108 $ 0.270 January 31, 2018 $ 2.46 $ 0.355 October 31, 2017 $ 0.52 $ 0.047 July 31, 2017 $ 0.125 $ 0.054 April 30, 2017 $ 0.145 $ 0.054 January 31, 2017 $ 0.145 $ 0.020 ____________ (1) Over-the-counter market quotations reflect inter-dealer prices without retail mark-up, mark-down or commission, and may not represent actual transactions. As of May 2, 2019, there were approximately 97 active holders of record of our common stock. As of such date, 106,244,230 common shares were issued and outstanding. Our common shares are issued in registered form. National Issuer Services Ltd., 760 – 777 Hornby Street, Vancouver, BC Canada V6Z 1S4, telephone number (604)559-8880, is the registrar and transfer agent for our common shares. Dividend Policy We have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined from time to time by our board of directors. Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities Other than as set out below, we did not sell any equity securities which were not registered under the Securities Act during the year ended January 31, 2019 that were not otherwise disclosed on our quarterly reports on Form 10-Q or our current reports on Form 8-K filed during the year ended January 31, 2019. On March 5, 2019, we issued 100,000 shares of common stock to a third party as a loan origination fee. On March 23, 2019, we issued 35,714 to a third party for services provided. On March 23, 2019, we issued 690,323 shares of common stock to directors and officers to settle outstanding compensation and 1,000,000 shares of common stock to a third party for services provided. On April 8, 2019, we issued 60,515 shares of common stock as an extension fee for an outstanding obligation. These shares of common stock were issued to five (5) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933, and seven (7) U.S. person (as that term is defined in Regulation S of the Securities Act of 1933), relying upon Rule 506 of Regulation D of the Securities Act of 1933. 16 Table of Contents Effective April 8, 2019, we closed a private placement for an aggregate of 6,950,000 units, consisting of one common share and one share purchase warrant, at price of $0.20 per unit, for gross proceeds of $1,390,000. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.30 per share and has an expiry term of three (3) years. In connection with this private placement, we issued 6,950,000 common shares and 6,950,000 share purchase warrants to eleven (11) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. Finders’ fees consisted of cash payments of $80,000 and issuance of 508,000 shares of common stock and 108,000 share purchase warrants entitling the holders to purchase one common share at a price of $0.30 per share and has an expiry term of three (3) years. In connection with the finders’ fees, we issued 508,000 shares of common stock to three (3) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933 and issued 108,000 share purchase warrants to one (1) non U.S. persons (as that term as defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. Equity Compensation Plan Information Except as disclosed below, we do not have a stock option plan in favor of any director, officer, consultant or employee of our company. Convertible Securities As of May 2, 2019, we had 13,691,833 outstanding options to purchase shares of our common stock at exercise prices ranging from $0.07 to $1.67 and exercisable until October 28, 2023. As of May 2, 2019, we had outstanding warrants to purchase 15,544,048 shares of our common stock at exercise prices ranging between of $0.60 and $1.74 and exercisable until October 18, 2021. Purchase of Equity Securities by the Issuer and Affiliated Purchasers We did not purchase any of our shares of common stock or other securities during our fourth quarter of our fiscal year ended January 31, 2019. Item 6. Selected Financial Data As a “smaller reporting company”, we are not required to provide the information required by this Item.